Boehringer Ingelheim names new U.S. leader
Boehringer Ingelheim will soon have new executive leadership in the United States. Jean-Michel Boers has been appointed to succeed Wolfgang Baiker, U.S. country managing director, president and CEO, who is retiring after 31 years on July 31. Boers' appointment is effective Aug. 1.
Boers, currently president of Boehringer Ingelheim is responsible for the U.S. commercial and medical organization, ensuring the successful development of the company’s current primary and specialty care portfolio, and preparing for future launches. He joined Boehringer Ingelheim in 1998 in Belgium and advanced through various roles in corporate and operating units, including corporate vice president, marketing and sales effectiveness, country managing director for France and human pharma head of a European region consisting of mid-sized countries.
“Today’s pace of change in healthcare is exponential, and Jean-Michel’s ability to translate vision and strategy into world-class execution is exactly what Boehringer Ingelheim needs as we enter our next chapter,” said Baiker. “With an incredible track record in leading significant growth and transformation of our human pharma business, Jean-Michel has a strong ability to build and lead highly-successful teams, and is a strong champion of Boehringer Ingelheim’s culture.”
Boers came to the United States in 2016 as senior vice president of the specialty care franchise, and since January 2017, he has led the U.S. human pharma business. He earned a master’s degree in social and economic history from the University of Nijmegen in the Netherlands and an MBA from the University of Texas.
“It has been a great pleasure to work with Wolfgang Baiker, and it is an honor to succeed him in leading our U.S. organization. I am humbled by the responsibility to continue Boehringer Ingelheim’s legacy of transforming the lives of our patients and animals,” said Boers. “I look forward to our continued scientific advancements and leading our dynamic U.S. organization.”
During his more than three-decade tenure at Boehringer Ingelheim, Baiker has held a number of senior leadership roles in the United States and in Europe across multiple businesses and functions, including head of international project management, head of global development, and member of the board of managing directors responsible for corporate board division biopharmaceuticals and operations.
Prior to his most recent assignment as country managing director, president and CEO for the United States, he spent two years as senior vice president human pharma supply & global quality and head of the biopharma business unit. During his time leading the U.S. organization.
Baiker has successfully leveraged his cross-functional experience and global network to position Boehringer Ingelheim for continued success, the company said.